This could be contradictory given that bDMARDs have been shown to reduce the CVD risk in RA patients, especially anti-TNF therapy, which exhibits a variety of myocardial protective mechanisms including promoting cholesterol transport, improving glucose metabolism, downregulating adhesion molecules, and resisting the effects of inflammation on blood coagulation (104). Here, TNF is linked to rheumatoid arthritis.